This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
Listen: HotCopper Wire Podcast #047 – Maybe just send an email next time, Albo
In this week’s HotCopper Wire episode, Isaac McIntyre and Jonathon Davidson break down (poke holes in) Albo’s national address from 7PM Wednesday, talk
- Isaac McIntyre
- 2 mins
- 02 April 2026 14:30 (AEST)
Introducing Prairie Lithium: Saskatchewan’s permitted lithium project ready to scale
We've spoken to Prairie Lithium founder Zach Maurer about the explorer's overall mission, right after Macquarie's…
- Isaac McIntyre
- 1 min
- 31 March 2026 16:17 (AEST)
US growth, injectable iron pipeline: How AFT Pharma is driving toward $300 million by FY27
AFT Pharmaceuticals (ASX:AFP) is in a red-hot position as we head straight into FY26’s fourth quarter in Australia, and
- Isaac McIntyre
- 2 mins
- 07 April 2026 09:15 (AEST)
HotCopper Highlights, Week 15: Santos, Karoon, Viva all riding the Iran-fuelled Energy rollercoaster
Hello, hello, and welcome to HotCopper Highlights for Week 15, CY26, I’m Isaac McIntyre.
- Isaac McIntyre
- 3 mins
- 10 April 2026 15:38 (AEST)
